CRS appoints Catherine Canales as new Chief Commercial Officer to fuel strategic development and international growth
EQS-News: CRS Clinical Research Services Management GmbH / Key word(s): Personnel
CRS appoints Catherine Canales as new Chief Commercial Officer to fuel strategic development and international growth
10.04.2024 / 11:00 CET/CEST
The issuer is solely responsible for the content of this announcement.* CRS appoints Catherine Canales as new Chief Commercial Officer *
*to fuel strategic development and international growth*
*Mannheim, Germany, April 10, 2024* – CRS Clinical Research Services, an expert early-phase Contract Research Organization (CRO), today announced the appointment of Catherine Canales as Chief Commercial Officer (CCO), effective today, completing the new CRS leadership team. Together, they are committed to steering the company's strategic development, growth, and innovation on a global scale.
Dr. Elisabeth Lackner, CEO of CRS, commented on the appointment: “It is a great pleasure to welcome Catherine on board the CRS management team. Catherine's induction is a pivotal moment in our pursuit of internationalization and superior service quality. Her proven expertise, forward-thinking approach, and collaborative leadership style align perfectly with CRS' needs, as we continuously adapt to the changing landscape of clinical research. Aligned with our strategy, Catherine has a strong focus on client satisfaction and positive client experiences. Together, we are poised for unparalleled growth and success.”
Catherine Canales, CCO of CRS, emphasized: “At the core of CRS’ success is a steadfast commitment to outstanding service for our clients and their patients. By adopting a leadership style that champions change and innovation, we aim to create a culture where excellence in client service is the norm. Our dedication to enhancing our team's skills will allow us to exceed our clients' expectations, thereby strengthening relationships and providing customized solutions. This commitment to excellence in service is the cornerstone of our future strategy and will propel our collective efforts towards achieving exceptional results together.”
Catherine brings over two decades of experience in the clinical research services industry to CRS. Her outstanding track record in business development, growth strategy implementation, and strategic marketing stands as a testament to her expertise. She joins from Labcorp Central Laboratory Services, where she held the position of European Sales Director, Business Development Coach, and Senior Director of Strategic Accounts, leading business development, marketing, and sales activities in the biotech sector. Prior to that, she was Senior Director, Business Development at Labcorp Drug Development (now Fortrea), responsible for the global commercial relationship for one of the company’s key accounts. Before that, she served as Director, Business Development at Premier Research, driving business growth and sales by promoting phase I-IV clinical development services. Catherine obtained a Master’s degree in Business Sciences from Lugano Business School and completed various post-graduate trainings, covering subjects ranging from marketing and executive coaching to clinical trials and regulatory affairs.
*About CRS Clinical Research Services*
CRS Clinical Research Services Management GmbH, a leading early-phase CRO and multi-indication specialist, operates multiple study sites across Germany with a capacity of 200 in-house beds. CRS excels in conducting clinical trials spanning from First-in-Human to Proof-of-Concept studies, demonstrating proficiency across diverse therapeutic areas.
Established in 2006, CRS has emerged as a trusted partner for biopharmaceutical companies of all sizes, offering tailored strategic outsourcing. Its specialized study sites and research facilities are renowned for their recruiting capabilities, catering to a wide range of indications, including metabolic, cardiovascular, dermatologic, and women's health studies.
At CRS, a commitment to the well-being of patients and healthy volunteers as well as respect underpin every aspect of operations, reflecting the organization's unwavering adherence to the highest ethical and medical standards. CRS ensures expedited approval times, dependable recruitment, and efficient trial conduct while maintaining rigorous standards of consistency, quality, and safety.
For further details, please visit www.crs-group.de and follow us on LinkedIn.
For a high-resolution image of Catherine Canales, please contact crs@mc-services.eu
*Company Contact*
*CRS Clinical Research Services Management GmbH*
Dr. Elisabeth Lackner
Phone: +49 621 15045109
E-mail: info.management@crs-group.de
*Media Inquiries*
*MC Services AG*
Dr. Cora Kaiser
Phone: +49 89 2102280
E-mail: crs@mc-services.eu
--------------------
10.04.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com --------------------